RNTX
Rein Therapeutics Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$0.89
+5.39%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | 1.0K | — | — | — |
| Gross Profit | — | (1.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 10.4M | 11.0M | 14.2M | 4.0K | 18.0K |
| SG&A Expense | 10.4M | 10.9M | 13.9M | 11.4K | 9.7K |
| General & Admin Expense | 10.4M | 10.9M | 13.9M | 11.4K | 9.7K |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (1.0K) | 37.0M | 928.00 | — |
| Total Operating Expenses | 20.8M | 21.9M | 65.1M | 16.3K | 27.6K |
| Cost and Expenses | 20.8M | 21.9M | 65.1M | 16.3K | 27.6K |
| Operating Income (EBIT) | (20.8M) | (21.9M) | (65.1M) | (16.3K) | (27.6K) |
| Non-Operating | |||||
| Interest Income | — | — | 400.0K | 600.00 | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | 400.0K | 600.00 | — |
| Other Non-Op Income/Expense | (29.7M) | (28.7M) | 800.0K | 544.00 | 318.00 |
| Non-Operating Income (excl Interest) | 907.0K | 28.7M | (37.0M) | (928.00) | (318.00) |
| EBT (Pre-Tax Income) | (50.5M) | (50.6M) | (64.3M) | (15.7K) | (27.3K) |
| Income Tax Expense | (712.0K) | (712.0K) | (1.5M) | — | — |
| Bottom Line | |||||
| Net Income | (49.8M) | (49.9M) | (62.9M) | (15.7K) | (27.3K) |
| Earnings from Cont. Ops | (49.8M) | (49.9M) | (62.8M) | (15.7K) | (27.3K) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (49.8M) | (49.9M) | (62.9M) | (15.7K) | (27.3K) |
| Per Share | |||||
| Basic EPS | ($1.83) | ($1.96) | ($3.51) | ($3.42) | ($6.02) |
| Diluted EPS | ($1.83) | ($1.96) | ($3.51) | ($3.42) | ($6.02) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 30.4M | 25.4M | 17.9M | 4.6M | 4.5M |
| Diluted Shares Outstanding | 30.4M | 25.4M | 17.9M | 4.6M | 4.5M |
| Profitability Metrics | |||||
| EBITDA | (21.0M) | (50.6M) | (28.0M) | (15.2K) | (27.2K) |
| D&A | 623.0K | 1.0K | 63.0K | 119.00 | 169.00 |
| EBIT | (21.7M) | (50.6M) | (28.1M) | (15.3K) | (27.3K) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026